- |||||||||| rontalizumab (RG7415) / Roche, sifalimumab (MDX-1103) / AstraZeneca, Saphnelo (anifrolumab) / AstraZeneca
Targeting Type I IFN in SLE and lupus nephritis (Concert Hall) - Feb 25, 2024 - Abstract #LUPUS2024LUPUS_45;
The anifrolumab program reaffirmed the clinical significance of type I IFN in SLE and boosted confidence that other approaches to inhibit type I IFN would prove efficacious. This presentation will review various strategies being pursued in order to block the interferon pathway in SLE and lupus nephritis.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly
Renal Involvement and Novel Kidney Biopsy Findings in a Young Girl With Aicardi-Goutières Syndrome (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1308;
The effectiveness of JAK1/2 inhibitors in IFN with renal involvement has not been definitively established, but case reports have been encouraging. The correlation between JAK1/2 inhibition and clinical improvement in this case supports the use of baricitinib in other interferon-related disorders.
|
